Tremor and other hyperkinetic movements (New York, N.Y.) · 2026
A Case of Cala Trio-Induced Glossopharyngeal Neuralgia in a Patient with Essential Tremor and Idiopathic Parkinson's Disease.
Клинический случайСтатьяПоддержка исследования: вне правительства СШАПоддержка NIH: внешняя программаНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Arnold Moriah R, Hiller Amie L
Аннотация
BACKGROUND: Cala Trio is a wrist-worn transcutaneous afferent patterned stimulation (TAPS) device for essential tremor (ET), delivering high-frequency stimulation to the median and radial nerves.
CASE REPORT: We report the first case of glossopharyngeal neuralgia (GPN) associated with Cala Trio initiation in a 69-year-old male with ET and Parkinson's disease, with prior GPN. Throat spasms triggered by swallowing and coughing began after initiation on two trials and resolved with discontinuation; evaluation was unrevealing.
DISCUSSION: We review TAPS mechanisms, GPN neuroanatomy, and circuit-level links between peripheral nerve stimulation and brainstem cranial nerve hyperexcitability, highlighting a novel adverse event and need for caution in patients with prior GPN.
HIGHLIGHTS: We report the first case of glossopharyngeal neuralgia associated with Cala Trio TAPS therapy in a patient with essential tremor and Parkinson's disease. Symptoms were temporally linked to device use and resolved upon discontinuation, suggesting a reversible neuromodulation-related effect and expanding the safety profile of peripheral tremor therapies.
CASE REPORT: We report the first case of glossopharyngeal neuralgia (GPN) associated with Cala Trio initiation in a 69-year-old male with ET and Parkinson's disease, with prior GPN. Throat spasms triggered by swallowing and coughing began after initiation on two trials and resolved with discontinuation; evaluation was unrevealing.
DISCUSSION: We review TAPS mechanisms, GPN neuroanatomy, and circuit-level links between peripheral nerve stimulation and brainstem cranial nerve hyperexcitability, highlighting a novel adverse event and need for caution in patients with prior GPN.
HIGHLIGHTS: We report the first case of glossopharyngeal neuralgia associated with Cala Trio TAPS therapy in a patient with essential tremor and Parkinson's disease. Symptoms were temporally linked to device use and resolved upon discontinuation, suggesting a reversible neuromodulation-related effect and expanding the safety profile of peripheral tremor therapies.